Skip to main content

Travere Therapeutics, Inc.

TVTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001438533

In the last 90 days, Travere Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 320 institutions reported holding it in 13F filings for Q2 2026, worth $5.98B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Travere Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
10 filings
9 insiders, $67.0M in total
Insiders trading
9
Net value
−$67.0M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Travere Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Travere Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Rote William E.Chief Research Officer98,197Sep 17, 20266
Heerma PeterEVP, CHIEF COMMERCIAL OFFICER117,066Sep 17, 20267
Inrig JulaEVP, Head of R&D & CMO100,491Sep 17, 20268
Reed Elizabeth EChief Legal Officer and GC105,389Sep 17, 20269
Dube Eric MCHIEF EXECUTIVE OFFICER432,886Sep 17, 20268
Cline Christopher R.CHIEF FINANCIAL OFFICER87,508Sep 17, 20267
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER42,353Sep 17, 20266
Meckler Jeffrey ADirector91,500Sep 11, 20263
Lyons Gary ADirector61,500Aug 19, 20263
Coughlin TimothyDirector56,250Jun 16, 20264
Baynes Roy D.Director41,500Jun 16, 20266
Brinkley Ruth WilliamsDirector29,750May 21, 20261
Squarer RonDirector39,375May 21, 20261
Orwin John ADirector39,375May 21, 20261
Bruhn Suzanne LouiseDirector32,750May 21, 20261
Poole SandraDirector34,000May 21, 20261
Aselage SteveDirector146,919May 12, 20220
Clague LauraChief Financial Officer35,655May 12, 20220
Rosenberg Noah L.Chief Medical Officer47,614Aug 17, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 29, 2021 (view filing)Jul 281 dayRosenberg Noah L.Chief Medical OfficerSSale−1.25K$13.81−$17.3K−2.7%44.5K after
Aug 17, 2021 (view filing)Aug 17Same dayClague LauraChief Financial OfficerSSale−1.41K$17.12−$24.1K−4.3%31.3K after
Aug 17, 2021 (view filing)Aug 17Same dayReed Elizabeth ESVP, GC & Corporate SecretarySSale−1.41K$17.12−$24.1K−3.6%37.5K after
Aug 17, 2021 (view filing)Aug 17Same dayRote William E.Senior Vice President, R&DSSale−1.41K$17.12−$24.1K−3.8%35.7K after
Aug 17, 2021 (view filing)Aug 17Same dayRosenberg Noah L.Chief Medical OfficerSSale−1.41K$17.12−$24.1K−2.9%47.6K after
Aug 17, 2021 (view filing)Aug 17Same dayDube Eric MChief Executive OfficerSSale−7.84K$17.12−$134.2K−4.8%156.9K after
Aug 17, 2021 (view filing)Aug 17Same dayHeerma PeterChief Commercial OfficerSSale−1.41K$17.12−$24.1K−2.2%63.5K after
Oct 5, 2021 (view filing)Oct 41 dayHeerma PeterChief Commercial OfficerSSale−3.06K$24.77−$75.7K−4.8%60.5K after
Oct 8, 2021 (view filing)Oct 71 dayAselage SteveDirectorSSale−60.0K$26.25−$1.57M−24.0%189.8K after2 lots
Nov 3, 2021 (view filing)Nov 1-22 daysAselage SteveDirectorSSale−8.50K$29.69−$252.4K−30.4%19.5K after2 lots
Nov 9, 2021 (view filing)Nov 54 daysAselage SteveDirectorSSale−10.0K$26.23−$262.3K−5.8%161.8K after
Nov 18, 2021 (view filing)Nov 162 daysAselage SteveDirectorSSale−31.8K$29.39−$934.6K−17.5%149.5K after
Jan 6, 2022 (view filing)Jan 4-52 daysDube Eric MChief Executive OfficerSSale−17.3K$30.08−$521.4K−11.0%139.6K after3 lots
Jan 12, 2022 (view filing)Jan 111 dayClague LauraChief Financial OfficerSSale−7.50K$27.40−$205.5K−19.3%31.3K after
Jan 12, 2022 (view filing)Jan 111 dayRote William E.Senior Vice President, R&DSSale−2.50K$27.40−$68.5K−6.1%38.4K after
Jan 12, 2022 (view filing)Jan 111 dayReed Elizabeth ESVP, GC & Corporate SecretarySSale−5.00K$27.40−$137.0K−11.8%37.5K after
Jan 26, 2022 (view filing)Jan 242 daysDube Eric MChief Executive OfficerSSale−7.87K$24.98−$196.7K−5.6%131.7K after
Jan 26, 2022 (view filing)Jan 242 daysClague LauraChief Financial OfficerSSale−2.06K$24.98−$51.5K−6.6%29.3K after
Jan 26, 2022 (view filing)Jan 242 daysReed Elizabeth ESVP, GC & Corporate SecretarySSale−2.25K$24.98−$56.2K−6.0%35.3K after
Jan 26, 2022 (view filing)Jan 242 daysHeerma PeterChief Commercial OfficerSSale−1.88K$24.98−$46.8K−3.1%58.6K after
Jan 26, 2022 (view filing)Jan 242 daysRote William E.Senior Vice President, R&DSSale−1.88K$24.98−$46.8K−4.9%36.5K after
Jan 26, 2022 (view filing)Jan 242 daysCalvin SandraVP, Corp Controller and CAOSSale−934$24.58−$23.0K−3.2%28.7K after
Feb 2, 2022 (view filing)Jan 312 daysDube Eric MChief Executive OfficerSSale−4.81K$27.40−$131.9K−2.8%164.7K after
Feb 2, 2022 (view filing)Jan 312 daysClague LauraChief Financial OfficerSSale−1.24K$27.40−$33.9K−3.2%37.9K after
Feb 2, 2022 (view filing)Jan 312 daysHeerma PeterChief Commercial OfficerSSale−1.13K$27.40−$30.8K−1.6%67.3K after
Feb 2, 2022 (view filing)Jan 312 daysRote William E.Senior Vice President, R&DSSale−1.13K$27.40−$30.8K−2.4%45.2K after
Feb 2, 2022 (view filing)Jan 312 daysReed Elizabeth ESVP, GC & Corporate SecretarySSale−1.35K$27.40−$37.0K−3.0%43.8K after
Feb 2, 2022 (view filing)Jan 312 daysCalvin SandraVP, Corp Controller and CAOSSale−798$26.51−$21.2K−2.1%36.6K after
Feb 11, 2022 (view filing)Feb 101 dayDube Eric MChief Executive OfficerSSale−4.83K$27.84−$134.5K−2.9%159.9K after
May 12, 2022 (view filing)May 111 dayAselage SteveDirectorSSale−2.58K$21.92−$56.4K−1.7%146.9K after
May 12, 2022 (view filing)May 10-112 daysCalvin SandraSVP, Chief Accounting OfficerSSale−881$21.72−$19.1K−2.4%35.7K after2 lots
May 12, 2022 (view filing)May 10-112 daysClague LauraChief Financial OfficerSSale−2.20K$21.51−$47.3K−5.8%35.7K after2 lots
May 12, 2022 (view filing)May 10-122 daysReed Elizabeth ESVP, GC & Corporate SecretarySSale−1.95K$21.51−$41.9K−4.5%41.8K after2 lots
May 12, 2022 (view filing)May 111 dayRote William E.Senior Vice President, R&DSSale−1.56K$21.72−$33.9K−3.5%43.7K after2 lots
Sep 15, 2022 (view filing)Sep 132 daysCalvin SandraSVP, Chief Accounting OfficerSSale−349$28.00−$9.77K−1.0%35.9K after
Oct 6, 2022 (view filing)Oct 42 daysHeerma PeterChief Commercial OfficerSSale−3.04K$25.68−$78.1K−4.5%65.1K after
Jan 6, 2023 (view filing)Jan 4-52 daysInrig JulaChief Medical OfficerSSale−2.49K$20.75−$51.7K−12.5%17.5K after2 lots
Jan 6, 2023 (view filing)Jan 51 dayDube Eric MChief Executive OfficerSSale−5.63K$20.75−$116.7K−3.5%154.3K after
Jan 26, 2023 (view filing)Jan 242 daysHeerma PeterChief Commercial OfficerSSale−1.55K$21.90−$33.9K−2.4%63.6K after
Jan 26, 2023 (view filing)Jan 242 daysCline Christopher R.Chief Financial OfficerSSale−852$21.90−$18.7K−2.5%32.9K after
Jan 26, 2023 (view filing)Jan 242 daysDube Eric MChief Executive OfficerSSale−6.44K$21.50−$138.5K−4.2%147.8K after
Jan 26, 2023 (view filing)Jan 242 daysReed Elizabeth ESVP, GC & Corporate SecretarySSale−2.06K$21.50−$44.3K−4.9%39.8K after
Jan 26, 2023 (view filing)Jan 242 daysRote William E.Senior Vice President, R&DSSale−2.06K$21.50−$44.3K−4.6%42.4K after
Jan 26, 2023 (view filing)Jan 24-252 daysCalvin SandraSVP, Chief Accounting OfficerSSale−1.10K$21.85−$24.0K−3.1%34.8K after2 lots
Feb 2, 2023 (view filing)Feb 1-21 dayCalvin SandraSVP, Chief Accounting OfficerSSale−2.03K$21.87−$44.4K−4.5%42.8K after2 lots
Feb 2, 2023 (view filing)Feb 11 dayDube Eric MChief Executive OfficerSSale−8.20K$22.25−$182.4K−3.3%237.2K after
Feb 2, 2023 (view filing)Feb 11 dayCline Christopher R.Chief Financial OfficerSSale−1.59K$21.75−$34.5K−3.0%51.5K after
Feb 2, 2023 (view filing)Feb 11 dayHeerma PeterChief Commercial OfficerSSale−1.78K$21.75−$38.7K−2.1%82.1K after
Feb 2, 2023 (view filing)Feb 11 dayRote William E.Senior Vice President, R&DSSale−2.59K$22.25−$57.6K−4.1%60.0K after
Feb 2, 2023 (view filing)Feb 11 dayReed Elizabeth ESVP, GC & Corporate SecretarySSale−2.59K$22.25−$57.6K−4.3%57.4K after